Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2026)

Contineum Therapeutics' Interest & Investment Income history spans 4 years, with the latest figure at $2.5 million for Q1 2026.

  • Quarterly Interest & Investment Income rose 11.33% to $2.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Mar 2026, down 10.7% year-over-year, with the annual reading at $8.2 million for FY2025, 7.4% down from the prior year.
  • Interest & Investment Income came in at $2.5 million for Q1 2026, up from $2.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.7 million in Q3 2024 to a low of $401000.0 in Q1 2023.
  • The 4-year median for Interest & Investment Income is $2.0 million (2024), against an average of $1.9 million.
  • Year-over-year, Interest & Investment Income skyrocketed 307.98% in 2024 and then fell 28.6% in 2025.
  • Contineum Therapeutics' Interest & Investment Income stood at $1.8 million in 2023, then skyrocketed by 41.23% to $2.5 million in 2024, then decreased by 20.49% to $2.0 million in 2025, then rose by 24.63% to $2.5 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Interest & Investment Income are $2.5 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025).